NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $253.07 -0.67 (-0.26%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ALNY alerts:Sign Up Key Stats Today's Range$250.01▼$254.1850-Day Range$232.27▼$300.5552-Week Range$141.98▼$304.39Volume325,553 shsAverage Volume904,499 shsMarket Capitalization$32.64 billionP/E RatioN/ADividend YieldN/APrice Target$298.09Consensus RatingModerate Buy Company OverviewAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More… This Crisis Could Be Worse Than 2008 (Ad)Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street. Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreALNY MarketRank™: Alnylam Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 208th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 18 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($2.21) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -96.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -96.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 1,012.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.90% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 1.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.52 Percentage of Shares Shorted2.90% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 1.08%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.73 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for Alnylam Pharmaceuticals this week, compared to 11 articles on an average week.Search InterestOnly 4 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,100,703.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Stock News HeadlinesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,469 SharesNovember 28 at 8:13 AM | insidertrades.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Cut to "Hold" at StockNews.comDecember 1 at 2:43 AM | americanbankingnews.com"Start Earning Extra Income with Just $30"What if you could unlock a steady income stream from stocks priced under $30? Our new guide walks you through simple, effective options strategies designed for everyday investors. With step-by-step insights, you’ll learn how to transform familiar names like Ford and Intel into reliable monthly income generators.December 1, 2024 | Darwin (Ad)Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference TherapeuticsNovember 28 at 5:37 PM | markets.businessinsider.comOpinion | A Short Lesson in Drug CompetitionNovember 28 at 4:23 AM | msn.comAlnylam Pharma’s Regulatory Challenges and Market Uncertainty Lead to Hold RatingNovember 28 at 4:23 AM | markets.businessinsider.comAlnylam Pharma (ALNY) Gets a Buy from RBC CapitalNovember 28 at 4:23 AM | markets.businessinsider.comAlnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | businesswire.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has increased by 32.2% and is now trading at $253.07. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.36. The firm's revenue for the quarter was down 33.3% on a year-over-year basis. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include Baillie Gifford & Co. (3.79%), Geode Capital Management LLC (1.66%), Groupama Asset Managment (1.18%) and Bellevue Group AG (0.63%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Pushkal Garg, Michael W Bonney, Kevin Joseph Fitzgerald, Tolga Tanguler, Amy W Schulman, Steven M Paul, Dennis A Ausiello, David E I Pyott and Indrani Lall Franchini. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings10/31/2024Today12/01/2024Next Earnings (Confirmed)12/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$298.09 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside+17.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-15.86% Pretax Margin-15.33% Return on EquityN/A Return on Assets-8.38% Debt Debt-to-Equity Ratio31.64 Current Ratio2.75 Quick Ratio2.69 Sales & Book Value Annual Sales$2.09 billion Price / Sales15.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book1,012.28Miscellaneous Outstanding Shares128,981,000Free Float127,046,000Market Cap$32.64 billion OptionableOptionable Beta0.39 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ALNY) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
